Jak2m1Dlbr/Jak2+
involves: 129S1/SvImJ * C57BL/6J
|
decreased erythrocyte cell number |
J:207740
|
normal
hematopoietic system phenotype |
J:207740
|
increased megakaryocyte cell number |
J:207740
|
thrombocytosis |
J:207740
|
Jak2m1Dlbr/Jak2m1Dlbr
involves: 129S1/SvImJ * C57BL/6J
|
anemia |
J:207740
|
lethality throughout fetal growth and development, complete penetrance |
J:207740
|
Jak2m1Dlbr/Jak2tm1Jni
involves: 129P2/OlaHsd * 129S1/SvImJ * C57BL/6J
|
anemia |
J:207740
|
lethality throughout fetal growth and development, complete penetrance |
J:207740
|
Jak2tm1(JAK2)Argr/Jak2+ Tg(Mx1-cre)1Cgn/0
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
abnormal bone marrow cell morphology/development |
J:164539
|
abnormal common myeloid progenitor cell morphology |
J:164539
|
abnormal erythropoiesis |
J:164539
|
abnormal hematopoietic system physiology |
J:164539
|
abnormal megakaryocyte differentiation |
J:164539
|
anemia |
J:164539
|
decreased hematopoietic stem cell number |
J:164539
|
decreased leukocyte cell number |
J:164539
|
enlarged spleen |
J:164539
|
increased erythrocyte cell number |
J:164539
|
increased erythroid progenitor cell number |
J:164539
|
increased hematocrit |
J:164539
|
increased hemoglobin content |
J:164539
|
increased leukocyte cell number |
J:164539
|
increased megakaryocyte cell number |
J:164539
|
myelofibrosis |
J:164539
|
thrombocytosis |
J:164539
|
Jak2tm1(JAK2)Argr/Jak2+ Dppa3tm1(cre)Peli/Dppa3+
involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6
|
abnormal protein level |
J:233169
|
increased chronic myelocytic leukemia incidence |
J:233169
|
increased hematopoietic stem cell number |
J:233169
|
increased leukocyte cell number |
J:233169
|
increased spleen weight |
J:233169
|
thrombocytosis |
J:233169
|
Jak2tm1.1Ble/Jak2+ Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: 129 * C57BL/6 * C57BL/10 * CBA/Ca
|
abnormal blood coagulation |
J:257910
|
abnormal blood vessel morphology |
J:257910
|
abnormal cytokine level |
J:257910
|
abnormal erythrocyte morphology |
J:257910
|
abnormal thrombosis |
J:257910
|
enlarged spleen |
J:257910
|
extramedullary hematopoiesis |
J:257910
|
increased erythrocyte cell number |
J:257910
|
increased erythroid progenitor cell number |
J:257910
|
increased granulocyte number |
J:257910
|
increased heart rate |
J:257910
|
increased leukocyte cell number |
J:257910
|
increased megakaryocyte cell number |
J:257910
|
increased megakaryocyte progenitor cell number |
J:257910
|
increased neutrophil cell number |
J:257910
|
limb paralysis |
J:257910
|
premature death |
J:257910
|
reticulocytosis |
J:257910
|
tachypnea |
J:257910
|
thrombocytosis |
J:257910
|
Jak2tm1.1Ble/Jak2tm1.1Ble
involves: 129S6/SvEvTac * C57BL/6
|
prenatal lethality, complete penetrance |
J:160883
|
Jak2tm1.1Jlvl/Jak2tm1.1Jlvl
involves: 129S2/SvPas * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:163497
|
abnormal common myeloid progenitor cell morphology |
J:163497
|
abnormal erythrocyte morphology |
J:163497
|
abnormal spleen morphology |
J:163497
|
anisocytosis |
J:163497
|
decreased circulating iron level |
J:163497
|
decreased mean corpuscular volume |
J:163497
|
decreased spleen white pulp amount |
J:163497
|
enlarged spleen |
J:163497
|
extramedullary hematopoiesis |
J:163497
|
giant platelets |
J:163497
|
increased erythrocyte cell number |
J:163497
|
increased erythroid progenitor cell number |
J:163497
|
increased granulocyte number |
J:163497
|
increased hematocrit |
J:163497
|
increased leukocyte cell number |
J:163497
|
increased lymphocyte cell number |
J:163497
|
increased mean platelet volume |
J:163497
|
increased megakaryocyte cell number |
J:163497
|
increased monocyte cell number |
J:163497
|
increased spleen red pulp amount |
J:163497
|
microcytosis |
J:163497
|
poikilocytosis |
J:163497
|
polychromatophilia |
J:163497
|
premature death |
J:163497
|
thrombocytosis |
J:163497
|
Jak2tm1.1Kuw/Jak2tm1.1Kuw
involves: 129X1/SvJ
|
abnormal erythropoiesis |
J:90883
|
prenatal lethality, complete penetrance |
J:90883
|
Jak2tm1.2Ble/Jak2+
involves: 129S6/SvEvTac * C57BL/6 * FVB/N
|
abnormal definitive hematopoiesis |
J:160883
|
abnormal erythropoiesis |
J:160883
|
abnormal hematopoietic system physiology |
J:160883
|
abnormal megakaryocyte morphology |
J:160883
|
abnormal spleen morphology |
J:160883
|
abnormal spleen red pulp morphology |
J:160883
|
enhanced megakaryocyte emperipolesis |
J:160883
|
enlarged spleen |
J:160883
|
extramedullary hematopoiesis |
J:160883
|
normal
hematopoietic system phenotype |
J:160883
|
increased erythroid progenitor cell number |
J:160883
|
increased hematocrit |
J:160883
|
increased hemolymphoid system tumor incidence |
J:160883
|
increased leukocyte cell number |
J:160883
|
increased megakaryocyte cell number |
J:160883
|
premature death |
J:160883
|
Jak2tm1.2Ble/Jak2tm1.2Ble
involves: 129S6/SvEvTac * C57BL/6 * FVB/N
|
prenatal lethality, complete penetrance |
J:160883
|
Jak2tm1Jni/Jak2+
involves: 129P2/OlaHsd
|
decreased erythrocyte cell number |
J:207740
|
normal
hematopoietic system phenotype |
J:207740
|
thrombocytosis |
J:207740
|
Jak2tm1Jni/Jak2tm1Jni
involves: 129P2/OlaHsd
|
abnormal erythropoiesis |
J:47299
|
abnormal megakaryocyte differentiation |
J:47299
|
anemia |
J:207740
|
extramedullary hematopoiesis |
J:47299
|
lethality throughout fetal growth and development, complete penetrance |
J:207740
|
prenatal lethality, complete penetrance |
J:47299
|
Jak2tm1Kf/Jak2+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal enzyme/coenzyme activity |
J:112700
|
normal
hematopoietic system phenotype |
J:112700
|
Jak2tm1Kf/Jak2tm1Kf
involves: 129S1/Sv * 129X1/SvJ
|
abnormal erythropoiesis |
J:112700
|
decreased embryo size |
J:112700
|
embryonic lethality, complete penetrance |
J:112700
|
Jak2tm1Kpf/Jak2tm1Kpf
either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129P2/OlaHsd * CD-1)
|
absent common myeloid progenitor cells |
J:47298
|
anemia |
J:47298
|
embryonic lethality during organogenesis, complete penetrance |
J:47298
|
impaired hematopoiesis |
J:47298
|
Jak2tm1Kuw/Jak2tm1Kuw
involves: 129X1/SvJ
|
no abnormal phenotype detected |
J:90883
|
Jak2tm1Kuw/Jak2tm1Kuw Tg(Gnrh1-cre)35Awo/0
involves: 129X1/SvJ * CD-1
|
abnormal estrous cycle |
J:167849
|
abnormal neuron physiology |
J:167849
|
decreased circulating luteinizing hormone level |
J:167849
|
decreased corpora lutea number |
J:167849
|
decreased litter size |
J:167849
|
decreased ovary weight |
J:167849
|
decreased ovulation rate |
J:167849
|
delayed estrous cycle |
J:167849
|
delayed female fertility |
J:167849
|
delayed sexual maturation |
J:167849
|
delayed vaginal opening |
J:167849
|
normal
homeostasis/metabolism phenotype |
J:167849
|
normal
nervous system phenotype |
J:167849
|
prolonged diestrus |
J:167849
|
prolonged metestrus |
J:167849
|
reduced female fertility |
J:167849
|
short proestrus |
J:167849
|
Jak2tm1Kuw/Jak2tm1Kuw Tg(MMTV-cre)1Mam/0
involves: 129X1/SvJ * C57BL/6 * FVB
|
abnormal mammary gland development |
J:90883
|
abnormal mammary gland growth during pregnancy |
J:90883
|
lactation failure |
J:90883
|
Jak2tm1Kuw/Jak2tm1Kuw Tg(Wap-cre)11738Mam/0
involves: 129X1/SvJ * C57BL/6 * FVB
|
abnormal mammary gland growth during lactation |
J:90883
|
Jak2tm1Mohi/Jak2+ Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA
|
abnormal bone marrow cavity morphology |
J:183821
|
abnormal bone marrow cell morphology/development |
J:183821
|
abnormal common myeloid progenitor cell morphology |
J:183821
|
abnormal spleen red pulp morphology |
J:183821
|
abnormal spleen white pulp morphology |
J:183821
|
decreased B cell number |
J:183821
|
enlarged spleen |
J:183821
|
increased erythrocyte cell number |
J:183821
|
increased erythroid progenitor cell number |
J:183821
|
increased hematocrit |
J:183821
|
increased hematopoietic stem cell number |
J:183821
|
increased hemoglobin content |
J:183821
|
increased leukocyte cell number |
J:183821
|
increased megakaryocyte cell number |
J:183821
|
increased neutrophil cell number |
J:183821
|
increased spleen red pulp amount |
J:183821
|
increased spleen weight |
J:183821
|
microcytosis |
J:183821
|
myelofibrosis |
J:183821
|
myeloid hyperplasia |
J:183821
|
polycythemia |
J:183821
|
reticulocytosis |
J:183821
|
spleen fibrosis |
J:183821
|
thrombocytosis |
J:183821
|
Jak2tm1Mohi/Jak2tm1Mohi Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA
|
abnormal bone marrow cavity morphology |
J:183821
|
abnormal bone marrow cell morphology/development |
J:183821
|
abnormal common myeloid progenitor cell morphology |
J:183821
|
abnormal spleen red pulp morphology |
J:183821
|
abnormal spleen white pulp morphology |
J:183821
|
decreased B cell number |
J:183821
|
decreased bone marrow cell number |
J:183821
|
decreased spleen white pulp amount |
J:183821
|
enlarged spleen |
J:183821
|
increased erythrocyte cell number |
J:183821
|
increased erythroid progenitor cell number |
J:183821
|
increased hematocrit |
J:183821
|
increased hematopoietic stem cell number |
J:183821
|
increased hemoglobin content |
J:183821
|
increased leukocyte cell number |
J:183821
|
increased megakaryocyte cell number |
J:183821
|
increased neutrophil cell number |
J:183821
|
increased spleen red pulp amount |
J:183821
|
increased spleen weight |
J:183821
|
microcytosis |
J:183821
|
myelofibrosis |
J:183821
|
myeloid hyperplasia |
J:183821
|
polycythemia |
J:183821
|
reticulocytosis |
J:183821
|
spleen fibrosis |
J:183821
|
thrombocytosis |
J:183821
|
Jak2tm2.1Jlvl/Jak2+ Tg(Vav1-cre)#Cgp/0
involves: 129S2/SvPas * C57BL/6NTac
|
abnormal bone marrow cell physiology |
J:202234
|
abnormal definitive hematopoiesis |
J:202234
|
abnormal myelopoiesis |
J:202234
|
decreased B cell number |
J:202234
|
decreased bone marrow cell number |
J:202234
|
decreased erythroblast number |
J:202234
|
enlarged spleen |
J:202234
|
extramedullary hematopoiesis |
J:202234
|
increased erythrocyte cell number |
J:202234
|
increased erythroid progenitor cell number |
J:202234
|
increased granulocyte number |
J:202234
|
increased hematocrit |
J:202234
|
increased hematopoietic stem cell number |
J:202234
|
increased hemoglobin content |
J:202234
|
increased leukocyte cell number |
J:202234
|
increased spleen weight |
J:202234
|
microcytosis |
J:202234
|
myelofibrosis |
J:202234
|
myeloid hyperplasia |
J:202234
|
reticulocytosis |
J:202234
|
spleen fibrosis |
J:202234
|
thrombocytosis |
J:202234
|
Jak2tm2.1Kpf/Jak2tm2.1Kpf
involves: 129P2/OlaHsd
|
abnormal cell physiology |
J:207710
|
abnormal embryonic erythropoiesis |
J:207710
|
embryonic lethality during organogenesis, complete penetrance |
J:207710
|
pallor |
J:207710
|
small liver |
J:207710
|
Jak2tm2.2Jlvl/Jak2+
involves: 129S2/SvPas * C57BL/6 * C57BL/6NTac * SJL
|
enlarged spleen |
J:202234
|
increased leukocyte cell number |
J:202234
|
polycythemia |
J:202234
|
thrombocytosis |
J:202234
|
Tg(H2-Kb-Jak2*V617F)2Shmd/0
involves: C57BL/6 * DBA/2
|
abnormal definitive hematopoiesis |
J:130189
|
abnormal megakaryocyte morphology |
J:130189
|
abnormal spleen morphology |
J:130189
|
anemia |
J:130189
|
decreased erythroblast number |
J:130189
|
decreased erythrocyte cell number |
J:130189
|
decreased erythroid progenitor cell number |
J:130189
|
decreased hematocrit |
J:130189
|
decreased hemoglobin content |
J:130189
|
enhanced megakaryocyte emperipolesis |
J:130189
|
enlarged spleen |
J:130189
|
giant platelets |
J:130189
|
increased compact bone thickness |
J:130189
|
increased leukocyte cell number |
J:130189
|
increased megakaryocyte cell number |
J:130189
|
increased neutrophil cell number |
J:130189
|
increased number of Howell-Jolly bodies |
J:130189
|
increased spleen red pulp amount |
J:130189
|
increased spleen weight |
J:130189
|
myelofibrosis |
J:130189
|
myeloid hyperplasia |
J:130189
|
polychromatophilia |
J:130189
|
spleen fibrosis |
J:130189
|
thrombocytosis |
J:130189
|